Hinge Health CFO James Budge sells $4.97m in stock

James Budge, Chief Financial Officer of Hinge Health, Inc. (NASDAQ:HNGE), sold 55,561 shares of the company’s Class A Common Stock on September 10, 2026, for a total value of approximately $4.97 million. The sale comes as the stock trades near its 52-week high of $95.57, following a remarkable 99% surge over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among the most overvalued stocks in the market.

The shares were sold at prices ranging from $88.2229 to $91.6175 per share. These transactions were executed pursuant to a Rule 10b5-1 trading plan, which Mr. Budge and his spouse adopted on June 11, 2026.

Following these sales, Mr. Budge directly holds 349,062 shares of Hinge Health Class A Common Stock. For deeper insights into Hinge Health’s valuation and performance, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.

In other recent news, Hinge Health reported second-quarter earnings that significantly surpassed expectations, with earnings per share at $0.59 compared to Wall Street’s estimate of $0.13. The company achieved a 53% increase in revenue, reaching $212.8 million, and doubled its operating income to $62 million, resulting in an expanded operating margin of 29%. Following these results, the company raised its full-year 2026 revenue and profit guidance. Additionally, Hinge Health announced plans to expand into the gastrointestinal health space through a $105 million acquisition of Cylinder Health. This move aligns with the company’s strategy to explore new growth areas, including migraine care. Analyst firms have responded positively to these developments, with Stifel raising its price target for Hinge Health to $115, citing a strong growth outlook. Truist Securities also increased its price target to $112, updating its financial model to reflect the company’s recent earnings and acquisition plans. Citizens raised its price target to $107, highlighting the company’s strategic expansion and recent performance.